About us

We operate a complete PET facility which includes:

• An 18MeV cyclotron
• Modern radiochemistry, radiopharmacy and quality control laboratories
• Contemporary PET/CT scanners supported by advanced RIS/PACS technology for image distribution.

Our principal use of PET in clinical practice is in oncology, with 80% of clinical scans being in cancer patients, and the remainder in neurology (epilepsy and dementia).

PET/CT images and reports are available via Health Link and Xero. We also can also send hard copies to external referrers.

Oncology referrals

¹⁸F-Fluorodeoxyglucose (FDG) continues to be the main radiotracer in use for characterising a range of tumours and to monitor the effects of various forms of therapy. There has been a steady increase in indications approved by Medicare for PET scans so most of the scans do not impose a charge to the patient. However there can be charges levied for certain unfunded indications and these are decided on a case by case basis.

Epilepsy referrals

¹⁸F-FDG PET is used to assist in the selection of patients for surgical treatment of epilepsy, especially temporal lobe epilepsy.

November 2025

Celebrating 13,315 years of service!

28 November 2025 - This week, we celebrated 743 staff who reached years of service milestones ranging from 10 to 45 years with our annual Years of Service Awards. Together, these staff have provided a staggering total of 13,315 years of service to Austin Health and our patients!

Austin Health launches inaugural Environmental, Social and Governance (ESG) Strategy 2025–2027

25 November 2025 - We’re proud to unveil Austin Health’s inaugural Environmental, Social and Governance (ESG) Strategy 2025-2027. This strategy builds on our legacy of care and innovation, aligning with our Strategic Plan 2023–2027 and our commitment to achieving net zero emissions by 2040.

Our equipment

Radiochemistry

We are equipped with the Cyclone 18/9 cyclotron, from IBA, that includes both a hydrogen and deuterium ion source. The cyclotron is equipped with a F-18 target, O-15 gas target, C-11 gas target and a Solid target system for production of I-124, Zr-89, Cu-64 and Yr-89. Additionally we also have a Gallium-68 generator.

Therefore, we are able to produce a wide range of radiotracers, such as ¹⁸F-FDG, ⁶⁸Ga-Dotatate, ⁶⁸Ga-PSMA, ¹⁸F-Fluorocholine, ⁸⁹Zr labelled antibodies, ¹¹C PiB, ¹¹C- PK11195, ¹⁸F-AV133 and Fluorinated amyloid tracers such as AV45 and NAV4694.

PET/CT scanners

We operate with three state of the art PET/CT scanners. Both Phillips Ingenuity TF128 scanners are used for clinical scans, whereas the Philips Gemini TF64 is used largely for neuroscience research scans. We are able to perform high resolution scans to answer the clinical question asked, in a relatively quick time, enabling a high patient throughput.

Our research

The research programs are focussed in the neuroscience and oncology areas, with specific emphasis on cognitive decline, tumour biology and psychiatry. We are internationally renowned for our ¹¹C  and ¹⁸Fligand research for studying the Amyloid  and Tau protein burden in patients with dementia. Novel PET tracers that interrogate receptor and signalling pathways in cancer cells are also being developed. These studies are aimed at expanding knowledge of the biology of cancer, and to assist in the development of new therapies through clinical trials in cancer patients at Austin Health. We have a number of active clinical trials at present.